Stockholders' (Deficit) Equity - Additional Information (Detail) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Nov. 05, 2019 |
Oct. 29, 2019 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Dec. 31, 2018 |
May 10, 2018 |
May 09, 2018 |
|
| Stockholders Equity [Line Items] | |||||||||
| Preferred stock, shares issued | 0 | 0 | 0 | ||||||
| Description of reverse stock split | At BIOLASE’s annual meeting of stockholders on May 9, 2018 (the “2018 Annual Meeting”), BIOLASE stockholders approved an amendment to BIOLASE’s Restated Certificate of Incorporation, as amended, to effect the Reverse Stock Split and on May 10, 2018, the Company filed an amendment (the “Amendment”) to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, effective as of 11:59 p.m. on May 10, 2018. The Amendment also reduced the authorized shares of common stock from 200,000,000 shares to 40,000,000 shares. Prior year share and per share amounts have been adjusted to reflect the impact of the Reverse Stock Split. | ||||||||
| Common stock, shares authorized | 40,000 | 40,000 | 40,000 | 40,000,000 | 200,000,000 | ||||
| Compensation expense related to stock options | $ 0.8 | $ 0.5 | $ 1.9 | $ 1.9 | |||||
| Total unrecognized compensation expense | $ 2.3 | $ 2.3 | |||||||
| Unrecognized share based compensation expense to be recognized over weighted-average period | 1 year 8 months 8 days | ||||||||
| Outstanding stock options, RSUs and warrants excluded from diluted loss per share | 5,600,000 | 3,200,000 | 5,600,000 | 3,200,000 | |||||
| Restricted Stock Units (RSUs) | |||||||||
| Stockholders Equity [Line Items] | |||||||||
| Granted | 1,900,000 | 2,200,000 | |||||||
| 2002 Stock Incentive Plan | |||||||||
| Stockholders Equity [Line Items] | |||||||||
| Common stock authorized for issuance | 3,100,000 | 3,100,000 | |||||||
| Common stock issued pursuant to options exercised | 1,000,000 | ||||||||
| Options and restricted stock units outstanding | 1,300,000 | 1,300,000 | |||||||
| Options available for future grants | 0 | 0 | |||||||
| 2018 Long-Term Incentive Plan | |||||||||
| Stockholders Equity [Line Items] | |||||||||
| Common stock authorized for issuance | 5,000,000 | 5,000,000 | |||||||
| Options and restricted stock units outstanding | 3,900,000 | 3,900,000 | |||||||
| Options available for future grants | 1,100,000 | 1,100,000 | |||||||
| Subsequent Event | |||||||||
| Stockholders Equity [Line Items] | |||||||||
| Net proceeds from issuance of shares after deducting underwriter discounts and other fees and expenses | $ 8.4 | $ 7.8 | |||||||
| Subsequent Event | Underwritten Public Offering | Common Stock | |||||||||
| Stockholders Equity [Line Items] | |||||||||
| Shares issued | 7,820,000 | ||||||||
| Subsequent Event | Private Placement | Series E Participating Convertible Preferred Stock | |||||||||
| Stockholders Equity [Line Items] | |||||||||
| Preferred stock, shares issued | 69,695 | ||||||||